Combination treatments of Ibrutinib and RSL3 or Ibrutinib and Erastin further decreased tumor sizes in relation to the control group and the single treatment group with further reduced expression levels of Nrf2, GPX4, SOD1 and CAT. This evidence concerns the gene GPX4 and neoplasm.